Cost-Effectiveness of Treatments Reducing Coronary Heart Disease Mortality in Ireland, 2000 to 2010
Abstract Objective Coronary heart disease (CHD) is associated with a large burden of disease in Ireland and is responsible for more than 6000 deaths annually. This study examined the cost-effectiveness of specific CHD treatments in Ireland. Methods Irish epidemiological data on patient numbers and m...
Gespeichert in:
| Veröffentlicht in: | Value in health 2009, Vol.12 (1), p.10-15 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 15 |
|---|---|
| container_issue | 1 |
| container_start_page | 10 |
| container_title | Value in health |
| container_volume | 12 |
| creator | Bennett, Kathleen, PhD Kabir, Zubair, MD, PhD Barry, Michael, MD Tilson, Lesley, PhD Fidan, Dogan, PhD Shelley, Emer, MD Capewell, Simon, MD |
| description | Abstract Objective Coronary heart disease (CHD) is associated with a large burden of disease in Ireland and is responsible for more than 6000 deaths annually. This study examined the cost-effectiveness of specific CHD treatments in Ireland. Methods Irish epidemiological data on patient numbers and median survival in specific groups, plus the uptake, effectiveness, and costs of specific interventions, all stratified by age and sex, were incorporated into a previously validated CHD mortality model, the IMPACT model. This model calculates the number of life-years gained (LYGs) by specific cardiology interventions to generate incremental cost-effectiveness ratios (ICERs) per LYG for each intervention. Results In 2000, medical and surgical treatments together prevented or postponed approximately 1885 CHD deaths in patients aged 25 to 84 years, and thus generated approximately 14,505 extra life-years (minimum 7270, maximum 22,475). In general, all the cardiac interventions investigated were highly cost-effective in the Irish setting. Aspirin, beta-blockers, ACE inhibitors, spironolactone, and warfarin for specific conditions were the most cost-effective interventions ( |
| doi_str_mv | 10.1111/j.1524-4733.2008.00398.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_754135009</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1098301510606663</els_id><sourcerecordid>754135009</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5638-9edf6693e67ea766828ad235be9dc01eeb3642467ef006776c3b936c65dc3c293</originalsourceid><addsrcrecordid>eNqNUsFu1DAQtRAVLYVfQL5xIWEcx04iISRYFrZSERJtuVpee4K8ZOPWdkr373HYVZE4rS8z0rw3fn7PhFAGJcvn7aZkoqqLuuG8rADaEoB3bfnwhJw9Dp7mHrq24MDEKXke4wYAJK_EM3LKOqhByPqMmIWPqVj2PZrk7nHEGKnv6XVAnbY4pki_o52MG3_ShQ9-1GFHV6hDop9cRB2RfvUh6cGlHXUjvQg46NG-oVkV0ORzZfCCnPR6iPjyUM_Jzefl9WJVXH77crH4cFkYIXlbdGh7KTuOskHdSNlWrbYVF2vsrAGGuOayruo87fNDmkYavu64NFJYw03V8XPyer_3Nvi7CWNSWxcNDlkR-imqRtSMC4AjkDwjs28zst0jTfAxBuzVbXDb7IJioOYs1EbNlqvZcjVnof5moR4y9dXhkmm9RfuPeDA_A97tAb_dgLujF6sfq2VuMv3jno7Z03uHQUXjcDRoXchpKuvdMSLf_7fEDG50Rg-_cIdx46cw5swUU7FSoK7mLzU7w0CClJLzPy-1v0c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734130159</pqid></control><display><type>article</type><title>Cost-Effectiveness of Treatments Reducing Coronary Heart Disease Mortality in Ireland, 2000 to 2010</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Bennett, Kathleen, PhD ; Kabir, Zubair, MD, PhD ; Barry, Michael, MD ; Tilson, Lesley, PhD ; Fidan, Dogan, PhD ; Shelley, Emer, MD ; Capewell, Simon, MD</creator><creatorcontrib>Bennett, Kathleen, PhD ; Kabir, Zubair, MD, PhD ; Barry, Michael, MD ; Tilson, Lesley, PhD ; Fidan, Dogan, PhD ; Shelley, Emer, MD ; Capewell, Simon, MD</creatorcontrib><description>Abstract Objective Coronary heart disease (CHD) is associated with a large burden of disease in Ireland and is responsible for more than 6000 deaths annually. This study examined the cost-effectiveness of specific CHD treatments in Ireland. Methods Irish epidemiological data on patient numbers and median survival in specific groups, plus the uptake, effectiveness, and costs of specific interventions, all stratified by age and sex, were incorporated into a previously validated CHD mortality model, the IMPACT model. This model calculates the number of life-years gained (LYGs) by specific cardiology interventions to generate incremental cost-effectiveness ratios (ICERs) per LYG for each intervention. Results In 2000, medical and surgical treatments together prevented or postponed approximately 1885 CHD deaths in patients aged 25 to 84 years, and thus generated approximately 14,505 extra life-years (minimum 7270, maximum 22,475). In general, all the cardiac interventions investigated were highly cost-effective in the Irish setting. Aspirin, beta-blockers, ACE inhibitors, spironolactone, and warfarin for specific conditions were the most cost-effective interventions (<€3000/LYG), followed by the statins for secondary prevention (<€6500/LYG). Revascularization for chronic angina and primary angioplasty for myocardial infarction, although still cost-effective, had the highest ICER (between €12,000 and €20,000/LYG). Conclusions Using a comprehensive standardized methodology, cost-effectiveness ratios in this study clearly favored simple medical treatments for myocardial infarction, secondary prevention, angina, and heart failure.</description><identifier>ISSN: 1098-3015</identifier><identifier>EISSN: 1524-4733</identifier><identifier>DOI: 10.1111/j.1524-4733.2008.00398.x</identifier><identifier>PMID: 19040564</identifier><language>eng</language><publisher>Malden, USA: Elsevier Inc</publisher><subject>Aged ; Aged, 80 and over ; CHD mortality ; Coronary Disease - economics ; Coronary Disease - mortality ; Coronary Disease - prevention & control ; Cost effectiveness ; Cost-Benefit Analysis - trends ; Female ; heart disease ; Heart diseases ; Humans ; IMPACT model ; Internal Medicine ; Interventions ; Ireland ; Ireland - epidemiology ; Life Expectancy - trends ; Male ; Middle Aged ; Models, Biological ; Mortality ; Secondary prevention ; Secondary Prevention - economics</subject><ispartof>Value in health, 2009, Vol.12 (1), p.10-15</ispartof><rights>International Society for Pharmacoeconomics and Outcomes Research (ISPOR)</rights><rights>2009 International Society for Pharmacoeconomics and Outcomes Research (ISPOR)</rights><rights>2008, International Society for Pharmacoeconomics and Outcomes Research (ISPOR)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5638-9edf6693e67ea766828ad235be9dc01eeb3642467ef006776c3b936c65dc3c293</citedby><cites>FETCH-LOGICAL-c5638-9edf6693e67ea766828ad235be9dc01eeb3642467ef006776c3b936c65dc3c293</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1524-4733.2008.00398.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1098301510606663$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,3537,4010,27900,27901,27902,30977,45550,45551,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19040564$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bennett, Kathleen, PhD</creatorcontrib><creatorcontrib>Kabir, Zubair, MD, PhD</creatorcontrib><creatorcontrib>Barry, Michael, MD</creatorcontrib><creatorcontrib>Tilson, Lesley, PhD</creatorcontrib><creatorcontrib>Fidan, Dogan, PhD</creatorcontrib><creatorcontrib>Shelley, Emer, MD</creatorcontrib><creatorcontrib>Capewell, Simon, MD</creatorcontrib><title>Cost-Effectiveness of Treatments Reducing Coronary Heart Disease Mortality in Ireland, 2000 to 2010</title><title>Value in health</title><addtitle>Value Health</addtitle><description>Abstract Objective Coronary heart disease (CHD) is associated with a large burden of disease in Ireland and is responsible for more than 6000 deaths annually. This study examined the cost-effectiveness of specific CHD treatments in Ireland. Methods Irish epidemiological data on patient numbers and median survival in specific groups, plus the uptake, effectiveness, and costs of specific interventions, all stratified by age and sex, were incorporated into a previously validated CHD mortality model, the IMPACT model. This model calculates the number of life-years gained (LYGs) by specific cardiology interventions to generate incremental cost-effectiveness ratios (ICERs) per LYG for each intervention. Results In 2000, medical and surgical treatments together prevented or postponed approximately 1885 CHD deaths in patients aged 25 to 84 years, and thus generated approximately 14,505 extra life-years (minimum 7270, maximum 22,475). In general, all the cardiac interventions investigated were highly cost-effective in the Irish setting. Aspirin, beta-blockers, ACE inhibitors, spironolactone, and warfarin for specific conditions were the most cost-effective interventions (<€3000/LYG), followed by the statins for secondary prevention (<€6500/LYG). Revascularization for chronic angina and primary angioplasty for myocardial infarction, although still cost-effective, had the highest ICER (between €12,000 and €20,000/LYG). Conclusions Using a comprehensive standardized methodology, cost-effectiveness ratios in this study clearly favored simple medical treatments for myocardial infarction, secondary prevention, angina, and heart failure.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>CHD mortality</subject><subject>Coronary Disease - economics</subject><subject>Coronary Disease - mortality</subject><subject>Coronary Disease - prevention & control</subject><subject>Cost effectiveness</subject><subject>Cost-Benefit Analysis - trends</subject><subject>Female</subject><subject>heart disease</subject><subject>Heart diseases</subject><subject>Humans</subject><subject>IMPACT model</subject><subject>Internal Medicine</subject><subject>Interventions</subject><subject>Ireland</subject><subject>Ireland - epidemiology</subject><subject>Life Expectancy - trends</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Models, Biological</subject><subject>Mortality</subject><subject>Secondary prevention</subject><subject>Secondary Prevention - economics</subject><issn>1098-3015</issn><issn>1524-4733</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNqNUsFu1DAQtRAVLYVfQL5xIWEcx04iISRYFrZSERJtuVpee4K8ZOPWdkr373HYVZE4rS8z0rw3fn7PhFAGJcvn7aZkoqqLuuG8rADaEoB3bfnwhJw9Dp7mHrq24MDEKXke4wYAJK_EM3LKOqhByPqMmIWPqVj2PZrk7nHEGKnv6XVAnbY4pki_o52MG3_ShQ9-1GFHV6hDop9cRB2RfvUh6cGlHXUjvQg46NG-oVkV0ORzZfCCnPR6iPjyUM_Jzefl9WJVXH77crH4cFkYIXlbdGh7KTuOskHdSNlWrbYVF2vsrAGGuOayruo87fNDmkYavu64NFJYw03V8XPyer_3Nvi7CWNSWxcNDlkR-imqRtSMC4AjkDwjs28zst0jTfAxBuzVbXDb7IJioOYs1EbNlqvZcjVnof5moR4y9dXhkmm9RfuPeDA_A97tAb_dgLujF6sfq2VuMv3jno7Z03uHQUXjcDRoXchpKuvdMSLf_7fEDG50Rg-_cIdx46cw5swUU7FSoK7mLzU7w0CClJLzPy-1v0c</recordid><startdate>2009</startdate><enddate>2009</enddate><creator>Bennett, Kathleen, PhD</creator><creator>Kabir, Zubair, MD, PhD</creator><creator>Barry, Michael, MD</creator><creator>Tilson, Lesley, PhD</creator><creator>Fidan, Dogan, PhD</creator><creator>Shelley, Emer, MD</creator><creator>Capewell, Simon, MD</creator><general>Elsevier Inc</general><general>Blackwell Publishing Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QJ</scope></search><sort><creationdate>2009</creationdate><title>Cost-Effectiveness of Treatments Reducing Coronary Heart Disease Mortality in Ireland, 2000 to 2010</title><author>Bennett, Kathleen, PhD ; Kabir, Zubair, MD, PhD ; Barry, Michael, MD ; Tilson, Lesley, PhD ; Fidan, Dogan, PhD ; Shelley, Emer, MD ; Capewell, Simon, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5638-9edf6693e67ea766828ad235be9dc01eeb3642467ef006776c3b936c65dc3c293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>CHD mortality</topic><topic>Coronary Disease - economics</topic><topic>Coronary Disease - mortality</topic><topic>Coronary Disease - prevention & control</topic><topic>Cost effectiveness</topic><topic>Cost-Benefit Analysis - trends</topic><topic>Female</topic><topic>heart disease</topic><topic>Heart diseases</topic><topic>Humans</topic><topic>IMPACT model</topic><topic>Internal Medicine</topic><topic>Interventions</topic><topic>Ireland</topic><topic>Ireland - epidemiology</topic><topic>Life Expectancy - trends</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Models, Biological</topic><topic>Mortality</topic><topic>Secondary prevention</topic><topic>Secondary Prevention - economics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bennett, Kathleen, PhD</creatorcontrib><creatorcontrib>Kabir, Zubair, MD, PhD</creatorcontrib><creatorcontrib>Barry, Michael, MD</creatorcontrib><creatorcontrib>Tilson, Lesley, PhD</creatorcontrib><creatorcontrib>Fidan, Dogan, PhD</creatorcontrib><creatorcontrib>Shelley, Emer, MD</creatorcontrib><creatorcontrib>Capewell, Simon, MD</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><jtitle>Value in health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bennett, Kathleen, PhD</au><au>Kabir, Zubair, MD, PhD</au><au>Barry, Michael, MD</au><au>Tilson, Lesley, PhD</au><au>Fidan, Dogan, PhD</au><au>Shelley, Emer, MD</au><au>Capewell, Simon, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost-Effectiveness of Treatments Reducing Coronary Heart Disease Mortality in Ireland, 2000 to 2010</atitle><jtitle>Value in health</jtitle><addtitle>Value Health</addtitle><date>2009</date><risdate>2009</risdate><volume>12</volume><issue>1</issue><spage>10</spage><epage>15</epage><pages>10-15</pages><issn>1098-3015</issn><eissn>1524-4733</eissn><abstract>Abstract Objective Coronary heart disease (CHD) is associated with a large burden of disease in Ireland and is responsible for more than 6000 deaths annually. This study examined the cost-effectiveness of specific CHD treatments in Ireland. Methods Irish epidemiological data on patient numbers and median survival in specific groups, plus the uptake, effectiveness, and costs of specific interventions, all stratified by age and sex, were incorporated into a previously validated CHD mortality model, the IMPACT model. This model calculates the number of life-years gained (LYGs) by specific cardiology interventions to generate incremental cost-effectiveness ratios (ICERs) per LYG for each intervention. Results In 2000, medical and surgical treatments together prevented or postponed approximately 1885 CHD deaths in patients aged 25 to 84 years, and thus generated approximately 14,505 extra life-years (minimum 7270, maximum 22,475). In general, all the cardiac interventions investigated were highly cost-effective in the Irish setting. Aspirin, beta-blockers, ACE inhibitors, spironolactone, and warfarin for specific conditions were the most cost-effective interventions (<€3000/LYG), followed by the statins for secondary prevention (<€6500/LYG). Revascularization for chronic angina and primary angioplasty for myocardial infarction, although still cost-effective, had the highest ICER (between €12,000 and €20,000/LYG). Conclusions Using a comprehensive standardized methodology, cost-effectiveness ratios in this study clearly favored simple medical treatments for myocardial infarction, secondary prevention, angina, and heart failure.</abstract><cop>Malden, USA</cop><pub>Elsevier Inc</pub><pmid>19040564</pmid><doi>10.1111/j.1524-4733.2008.00398.x</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1098-3015 |
| ispartof | Value in health, 2009, Vol.12 (1), p.10-15 |
| issn | 1098-3015 1524-4733 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_754135009 |
| source | Applied Social Sciences Index & Abstracts (ASSIA); MEDLINE; Wiley Online Library Journals Frontfile Complete; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Aged Aged, 80 and over CHD mortality Coronary Disease - economics Coronary Disease - mortality Coronary Disease - prevention & control Cost effectiveness Cost-Benefit Analysis - trends Female heart disease Heart diseases Humans IMPACT model Internal Medicine Interventions Ireland Ireland - epidemiology Life Expectancy - trends Male Middle Aged Models, Biological Mortality Secondary prevention Secondary Prevention - economics |
| title | Cost-Effectiveness of Treatments Reducing Coronary Heart Disease Mortality in Ireland, 2000 to 2010 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T11%3A41%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost-Effectiveness%20of%20Treatments%20Reducing%20Coronary%20Heart%20Disease%20Mortality%20in%20Ireland,%202000%20to%202010&rft.jtitle=Value%20in%20health&rft.au=Bennett,%20Kathleen,%20PhD&rft.date=2009&rft.volume=12&rft.issue=1&rft.spage=10&rft.epage=15&rft.pages=10-15&rft.issn=1098-3015&rft.eissn=1524-4733&rft_id=info:doi/10.1111/j.1524-4733.2008.00398.x&rft_dat=%3Cproquest_cross%3E754135009%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=734130159&rft_id=info:pmid/19040564&rft_els_id=1_s2_0_S1098301510606663&rfr_iscdi=true |